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ABSTRACT

Polyamine cationic lipids have been synthesized that have the
ability to be transported into cells having an active polyamine
transport system. Accordingly, these lipids may be conjugated with various agents and, thereby, act as vectors for
transporting the agent into the cell aided by the cell's own
polyamine transport system. A method of delivering an agent
into a cell includes associating the agent with a polyamine
cationic lipid selected from compounds 25, 26, 27, 28, their
pharmaceutically acceptable salts and combinations thereof
and contacting the cell therewith.
32 Claims, 8 Drawing Sheets
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Scheme 38 • Synthesis of the lipid-polyamine conjugates 15-19
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LIPOPHILIC POLYAMINES PROVIDING
ENHANCED INTRACELLULAR DELIVERY
OF AGENTS BY A POLYAMINE TRANSPORT
SYSTEM
RELATED APPLICATION
This application claims priority from provisional application Ser. No. 60/915,492, which was filed on May 2, 2007 and
which is incorporated herein by reference in its entirety.
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FIELD OF THE INVENTION
This invention relates to polyamines and, more specifically, to lipophilic polyamines effective in entering cells having an active polyamine transport system.

15

BACKGROUND OF THE INVENTION
With the information gained by the sequencing of the
human genome, 1•2 gene therapy now holds promise for the
treatment of hereditary diseases and cancers. 3•4 It is now
possible to silence a bad gene 5, tum on a needed gene 6, or
install a new gene to address particular cellular defects.7
However, a key requirement for successful gene therapy is the
efficient transfer of DNA to specific cell types in vivo. Viral
vectors have proven to be very efficient transfection agents
and allow for the insertion of foreign DNA into many cell
types. 8·9 However, the inherent problems with viral vectors
such as immunogenicity and the limited size of the DNA
plasmid that can be transferred has led to interest in developing efficient non-viral vectors. 10 - 14 Non-viral vectors are
ideal because of their expected low toxicity and immunogenicity, ability to transfer large strands of DNA and simpler
synthetic preparation. Typically, these vectors consist of a
lipophilic component attached to a positively charged, polar
headgroup, through the use of a spacer or linking motif, and
are a mixture of neutral and positively charged lipids. A wide
range of cationic liposomes have been synthesized and
recently reviewed. 15 -17 The cationic headgroups typically
found in these liposome systems include quaternary ammonium salts, 10 polylysine, 18 polyguanadinium salts, 19 polyarginine20 and polyamines. 21
Polyamines were introduced into liposomes by Behr, 22
when it was realized that the naturally-occurring polyamines
such as spermidine and spermine (FIG. 1) could efficiently
compact DNA. Behr went on to synthesize one of the first
transfection vectors, DOGS 1, and incorporated a branched
polyamine as the polar headgroup (FIG. 2). 11
Following this work, a number of research groups have
looked at the effect of changing the positively-charged,
polyamine headgroup on cationic liposomes with respect to
their efficiency at transfecting DNA. 15 ·16 ·21 ·23 ·24 Byk et al 21
showed that when assayed in HeLa cells, the compound RPR
120535 2, whose configuration of the polar head is linear, was
5-10 times more effective at transfection than those with
branched-, globular- or T-shaped polar domains. Safinya et
al 24 demonstrated with 3 that lipids containing a higher number of positive charges had better transfection efficiency
within a series of liposomes containing branched-polyamine
headgroups. Other popular vectors 4-6 are shown in FIG. 2.
Commercially-available Lipofectamine is a 3: 1 mixture of 4
and 6. 186
Although a large number of cationic lipids have been surveyed, a systematic study of how linear polyamine architectures effect transfection efficiency is still needed, especially
in light of the molecular recognition elements required to use

20

25

30

the polyamine transporter (PAT) for cellular entry. 25 -32 Our
goal was to perform the key crossover experiments needed to
tie these two fields together. Indeed, understanding how cationic motifs are transported across the cell membrane is critical to both enterprises.
Targeting a specific cellular transporter could provide cellselective transfection. For example, rapidly-proliferating
cancer cells could be targeted via their PAT, which is often
up-regulated. 28 Indeed, the ability to transfect a specific cell
type would have profound impact on a multitude of gene
therapy strategies.
Since many cancer cell lines have active polyamine transporters, it is possible to target these cells using the molecular
recognition events involved in polyamine import. 28 For
example, an anthracene-homospermidine conjugate was
shown to be 10-30 fold more toxic to B16 melanoma cells
than to 'normal' melanocytes (Mel-A cells). 28 A multitude of
polyamine structures were previously screened for their high
PAT selectivity in CHO and CHO-MG cells. 28 Several linear
polyamine architectures were identified, which selectively
targeted the PAT-active CHO cell line over its PAT-inactive
CHO-MG mutant. 25 -32 The discovery ofhomospermidine, a
4,4-triamine, as a cell-selective 'vector' motif provided the
means to test the PAT-delivery system as a conduit for gene
delivery. 26 •28
In short, our aim was to combine these two areas of
research (PAT targeting and gene delivery) by attaching PATtargeting polyamine sequences 28 to aryl lipid motif 3 24 in
order to facilitate DNA plasmid uptake. These materials were
then evaluated for their DNA-transporting ability as well as
transfection efficacy and compared to the commerciallyavailable transfection reagent, Lipofectamine 2000. 33
SUMMARY OF THE INVENTION
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With the foregoing in mind, the present invention advantageously provides a vector effective in delivering an agent
into a cell, said vector comprises a cationic lipid selected from
compounds according to formulas 25, 26, 27, 28, their pharmaceutically acceptable salts and combinations thereof.
Another embodiment of the invention includes a
polyamine cationic lipid vector effective in delivering an
agent into a cell in enhanced levels by being recognized by the
cell's polyamine transport system, said vector comprises
compound 26 or a pharmaceutically acceptable salt thereof.
A preferred method of the invention includes delivering an
agent into a cell, the method comprises associating the agent
with a polyamine cationic lipid selected from compounds 25,
26, 27, 28, their pharmaceutically acceptable salts and combinations thereof and contacting the cell therewith.
A further method of the invention includes delivering
enhanced levels of an agent into a cell, the method comprises
associating the agent with a polyamine cationic lipid according to compound 26 or a pharmaceutically acceptable salt
thereof and effective in being recognized by a polyamine
transport system in the cell.
The invention also includes a method of delivering
enhanced levels of an agent into target cells having an upregulated polyamine transporter, the target cells being among a
population of normal cells, the method comprises associating
the agent with a polyamine cationic lipid according to compound 26 or a pharmaceutically acceptable salt thereof and
contacting the cell population therewith so as to preferentially
deliver the polynucleotide into the target cells via the upregulated polyamine transporter system.
Yet another method of the invention is for treating a target
cell having an upregulated polyamine transporter, the method
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4

comprises associating an agent with a polyamine cationic
lipid according to compound 26 or a pharmaceutically
acceptable salt thereof and contacting the cell therewith.

channel to determine the percentage of cells that expressed
significant levels of GFP as compared with cells incubated
with DNA plasmid only; a gate was set just above the threshold measured with no DNA plasmid and no conjugate added
(almost negligible); all cells which exhibited a fluorescence
signal above that level were considered positive; data are
presented as the mean±SD; and
FIG. 12 shows [14C]Spermine uptake inhibition by 26;
tetraamine 26 is an efficient inhibitor of polyamine uptake;
CHO-Kl cells were incubated with 1 µM [ 14C]spermine (31
Ci/mo!) for 20 min in serum free medium supplemented with
varying concentrations of tetraamine 26 as indicated in the
figure; after extensive rinsing, imported [1 4 C]spermine was
determined by scintillation counting on cell lysates.

BRIEF DESCRIPTION OF THE DRAWINGS
Some of the features, advantages, and benefits of the
present invention having been stated, others will become
apparent as the description proceeds when taken in conjunction with the accompanying drawings, presented for solely
for exemplary purposes and not with intent to limit the invention thereto, and in which:
FIG. 1 shows naturally occurring polyamines, as known in
the prior art;
FIG. 2 illustrates additional previously known polyamines;
FIG. 3 is a diagram of synthetic scheme 1 of the present
invention;
FIG. 4 diagrams synthetic scheme 2 of the present invention;
FIG. 5 shows the flow of synthetic scheme 3 of the present
invention;
FIG. 6 shows synthetic scheme 4 of the present invention;
FIG. 7 depicts scheme 5, a final step in the present invention to produce the desired lipid-polyamine conjugates by
acidification of the amines with a solution of anhydrous HCI
in ethyl acetate;
FIG. 8 shows DNA uptake activity by novel cationic lipids
22-28 (compared with Lipofectamine, LFA). CHO Kl cells
were grown to confluence in 24-well plates, rinsed with
medium and incubated for 4 h at 3 7° C. with 1 µg/mL Alexa
Fluor-488-DNA complexed with 0.5 µg/mL (white bars), 2.5
µg/mL (gray bars), or 5 µg/mL (black bars) of the respective
cationic lipid, as indicated above each entry; cells were then
extensively washed with PBS, treated with trypsin, and cell
pellets were again extensively washed with PBS 1% BSA to
completely remove non-specific fluorescence from the cell
exterior; finally, cells were analyzed for Alexa Fluor-488DNA uptake by flow cytometry on a FACSCalibur (BD Biosciences) operated by Cell-Quest software. (*) during this
relatively short incubation (4 h), cells remained viable with
28; note: in converting from µg/mL to µM, the concentrations
used were typically approximately 0.6, 3 .0, and 6 µM, respectively;
FIG. 9 shows the results obtained from the experiment
described by FIG. 8, which were analyzed using a gated
channel to determine the percentage of cells that had internalized significant amounts of DNA as compared with cells
incubated with DNA only; a gate was set just above the
threshold signal for control cells (DNA only with no lipid
conjugate); note: Alexa Fluor-488-DNA complexed with 0.5
µg/mL (white bars), 2.5 µg/mL (gray bars), or 5 µg/mL (black
bars) of the respective cationic lipid was used, as indicated in
FIG. 8; data are presented as the mean±SD.
FIG. 10 illustrates GFP expression results from transfection experiments; CHO Kl cells were grown to approximately 50% sub-confluence in 24-well plates, rinsed with
medium and incubated for 4 hat 37° C. with 1 µg/mL eGFP
DNA plasmid complexed with 0.5 µg/mL (white bars), 2.5
g/mL (gray bars), or 5 µg/mL (black bars) of the respective
cationic lipid, as indicated above. Medium was then changed,
and cells were incubated for another 24 h to allow for GFP
plasmid expression; cells were detached by trypsin treatment
and analyzed for GFP expression by FACS; Lipofectamine is
denoted as LFA; the value obtained with DNA plasmid only
was subtracted from each entry above (almost negligible);
FIG. 11 shows the results obtained from the experiment
described in FIG. 10, which were analyzed using a gated
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The present invention will now be described more fully
hereinafter with reference to the accompanying drawings, in
which preferred embodiments of the invention are shown.
Unless otherwise defined, all technical and scientific terms
used herein have the same meaning as commonly understood
by one of ordinary skill in the art to which this invention
pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or
testing of the present invention, suitable methods and materials are described below. Any publications, patent applications, patents, or other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the
present specification, including any definitions, will control.
In addition, the materials, methods and examples given are
illustrative in nature only and not intended to be limiting.
Accordingly, this invention may, however, be embodied in
many different forms and should not be construed as limited
to the illustrated embodiments set forth herein. Rather, these
illustrated embodiments are provided so that this disclosure
will be thorough and complete, and will fully convey the
scope of the invention to those skilled in the art. Other features and advantages of the invention will be apparent from
the following detailed description, and from the claims.
As used herein, the term "pharmaceutically acceptable salt
or prodrug" is intended to describe any pharmaceutically
acceptable form (such as a salt of these amine systems with an
organic carboxylic acid like acetic acid or toluene-sulfonic
acid or methane sulfonic acid or an inorganic acid such as
HCI, HBr, phosphoric acid, or a related group or prodrug) of
a compound of the invention, which, upon administration to a
subject, provides the mature or base compound (e.g., the
lipophilic polyamine compound). Pharmaceutically acceptable salts include those derived from pharmaceutically
acceptable inorganic ororganic bases and acids. Suitable salts
include those derived from alkali metals such as potassium
and sodium, alkaline earth metals such as calcium and magnesium, among numerous other acids well known in the pharmaceutical art. Pharmaceutically acceptable prodrugs refer to
a compound that is metabolized, for example hydrolyzed or
oxidized, in the host to form the compound of the present
invention. Typical examples of prodrugs include compounds
that have biologically labile protecting groups on a functional
moiety of the active compound. Prodrugs include compounds
that can be oxidized, reduced, aminated, deaminated,
hydroxylated, dehydroxylated, hydrolyzed, dehydrolyzed,
alkylated, dealkylated, acylated, deacylated, phosphorylated,
dephosphorylated to produce the active compound.

US 7,910,363 Bl
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Results and Discussion
Synthesis.
A series of derivatives were synthesized with a variety of
linear polyamine headgroups. These cationic headgroups
contained from two to four positive charges. The convergent
synthetic route involved: a) the synthesis of the hydrophobic
lipid moiety, b) the synthesis of the BOC-protected amine
head groups, c) coupling of the two separate components
followed by d) the deprotection of the polyamine moiety to
furnish the final compounds as HCl salts.
The 3,4-disubstituted benzene containing lipids were chosen due to the significant success of these lipids in earlier
transfection studies by Safinya and others. 10023024 This structural element is also present in DOSPA 4 and DOTMA 5
(FIG. 2). The unsaturated unit within the ClS chain was
shown to prevent side chain recrystallisation and conferred a
high degree of flexibility upon the cationic liposomes. These
side chains were attached to the central benzene core via ether
linkages. An aldehyde or acid chloride in position 1 allowed
for attachment of the polyamine component. The polyamine
scaffolds and controls were identified in earlier investigations
of PAT-mediated drug delivery. 25 - 29
The first step was the synthesis of3,4-di(oleyloxy)benzaldehyde Sa by the 0-alkylation of 3,4-dihydroxy benzaldehyde 7a with oleyl bromide (Scheme 1 as shown in FIG. 3).
Similarly, the bis-0-alkylation of ethyl 3,4-dihydroxybenzoate 7b with oleyl bromide was used to form ethyl 3,4-di
(oleyloxy)benzoate Sb using the method ofSafinya et al., 23 •24
Subsequent cleavage of Sb with KOH was carried out to give
the acid Sc (Scheme 1) followed by treatment with oxalyl
chloride to give the desired acid chloride Sd.
As shown in Scheme 2 (FIG. 4), the next step in the synthesis involved the generation of the polyamine moieties:
N 1 -(tert-butoxycarbony1) putrescine 9, N 1 ,N4 -di-(tert-butoxycarbony l) homospermidine 12 34 and N 1 ,N4 ,N 8 -tri-(tertbutoxycarbonyl) homospermine 14 (Scheme 2). The mono
BOC protection of diaminobutane gave the amine 9 in a good
yield. Sequential addition of bromobutyronitrile, BOC protection of the newly formed secondary amine, followed by
reduction of the nitrile with Raney Ni gave masked triamine
12. Repetition of these three steps on 12 gave tri-BOC-protected tetraamine 14.
The coupling of the aldehyde Sa to a range of polyamines
was based on previous procedures for coupling of amines to
benzaldehydederivatives. 25 - 28 As showninScheme3 (shown
in FIG. 5), the reductive amination of Sa was achieved in two
steps via in situ generation of the imine (with a series of
amines) followed by reduction using NaBH4 to give the
respective 2° amines (15-19). As shown in Scheme 4 (shown
in FIG. 6), therespectivepolyamines 12 and 14 were coupled
to acid chloride Sd to provide the BOC-protected benzamide
systems, 20 and 21.
The final step to produce the desired lipid-polyamine conjugates involved acidification of the amines with a solution of
anhydrous HCl in ethyl acetate. 23024 As shown in Scheme 5
(shown in FIG. 7), treatment of the penultimate compounds
15-21 with anhydrous HCl/EtOAc provided the target HCl
salts, 22-2S. By design, the lipid portion of the conjugate
(boxed structure in Scheme 5) was held constant throughout
the series. This feature allowed for later comparisons and an
understanding of how the polyamine component influenced
DNA delivery.
Biological Evaluation.
Before conducting the transfection studies, the series of
conjugates (22-2S) were first evaluated for cytotoxicity in
Chinese Hamster Ovary (CHO) cells. This was an important
step in determining what dose of lipid-polyamine conjugate

could be tolerated by the cell line. Ideally, one would use a
dose of the conjugate, which is not cytotoxic to the cell line to
be transfected. This is an important caveat in evaluating DNA
delivery systems.
As expected, there were significant differences in the aqueous solubility of these new conjugates. DMSO was added in
portions to provide aqueous solutions of22-2S. Since DMSO
itself is toxic to CHO cells above 40 µM, stock solutions of
each conjugate were made in such a manner so that the total
DMSO concentration remained below 40 µM. This constraint
limited the amount of conjugate that could be dosed. Poorlysoluble materials required higher DMSO levels, which in tum
limited the amount of material that could be dosed to cells in
our toxicity screen.
Taking these factors into account, cytotoxicity screens
were performed to investigate the relative toxicity of each
system. Most materials were relatively non-toxic with IC 50
values ~20 µM. Armed with this insight, cells were treated
with ~6.4 µM of the polyamine conjugate so as to avoid
significant toxic effects from the delivery agent itself. Indeed,
at this dose ~90% of cells survived transfection for all compounds except 2S. Indeed, compound 2S was very toxic (after
24 h incubation) and even at the lowest dose used for transfection (0.5 µg/mL; 0.5 µM 2S) killed 95% of the cells. As
such, 2S was too toxic for efficient transfection at the doses
surveyed and its data is strongly biased by the few remaining
cells, which survived.
Gene Transfer Studies.
Armed with knowledge of the cytotoxicity range of the
series 22-2S, CHO-Kl cells were evaluated for DNA uptake
using a fluorescently labeled DNA Alexa Fluor-4SS-DNA).
As shown in FIG. 8, cells were dosed with the Alexa Fluor4SS-DNA in the presence of increasing concentrations (i.e.,
0.5, 2.5, 5 µg/mL) of the respective conjugate, 22-2S. Each
conjugate was as good (24, 25) or better (26, 27) than the
lipofectamine control (LFA, except 22 and 23) and facilitated
uptake of the fluorescent DNA probe in a concentrationdependent manner (µg/mL).
While the molecular weights in this series do range from
7S4 (22), S40 (23), S44 (24), S91 (25), 999 (26), S69 (27), and
976 g/mol (2S), they are relatively close (within 10-22%) and
allow for general comparisons, especially in light of the large
differences observed in activity. For example, tetraamine 26,
which has the highest molecular weight of the series (999
g/mol), was at a slightly lower concentration (5 µM) than 22
(6.4 µM) at the 5 µg/mL dose. Nevertheless, DNA uptake
experiments with tetraamine 26 had over a 5-fold increase in
DNA uptake (as measured by fluorescence of the imported
DNA probe) than those conducted with diamine 22. Clearly,
compound 26 was more efficient in facilitating DNA delivery
to cells.
Interestingly, conjugate 27, which represents a butanediamine motif similar to 22 except with the diamine placed
further away from the lipid tail, was a more efficient DNA
delivery agent than 22. In contrast, compound 23, which
separated the ammonium centers via an octanediamine had
similar or lower activity as 22 (depending on the dose). Insertion of the polyether motif present in 24 maintained this
eight-atom spacer, yet nearly doubled the DNA delivery
(DNA probe fluorescence) observed.
The PAT-selective homospermidine motif present in 25
resulted in a three-fold increase in DNA delivery. However,
this outcome may simply be due to the presence of the additional charge provided by the triamine motif present in 25.
Indeed, significant increases in DNA delivery were observed
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across the homologous series 22, 25, and26 which at 5 µg/mL
gave 94, 281 and 504 fluorescence absorbance units (a.u.),
respectively.
FIG. 8. shows DNA uptake activity by novel cationic lipids
22-28 (compared with Lipofectamine, LFA). CHO Kl cells
were grown to confluence in 24-well plates, rinsed with
medium and incubated for 4 h at 3 7° C. with 1 µg/mL Alexa
Fluor-488-DNA complexed with 0.5 µg/mL (white bars), 2.5
µg/mL (grey bars), or 5 µg/mL (black bars) of the respective
cationic lipid, as indicated above each entry. Cells were then
extensively washed with PBS, treated with trypsin, and cell
pellets were again extensively washed with PBS 1% BSA to
completely remove non-specific fluorescence from the cell
exterior. Finally, cells were analyzed for Alexa Fluor-488DNA uptake by flow cytometry on a FACSCalibur (BD Biosciences) operated by Cell-Quest software. (*) during this
relatively short incubation (4 h), cells remained viable with
28. Note: in converting from µg/mL to µM, the concentrations
used were typically approximately 0.6, 3 .0, and 6 µM, respectively and are tabulated specifically in the Supporting information.
In FIG. 9 we see the results obtained from the experiment
described by FIG. 8, which were analyzed using a gated
channel to determine the percentage of cells that had internalized significant amounts of DNA as compared with cells
incubated with DNA only. A gate was set just above the
threshold signal for control cells (DNA only with no lipid
conjugate). Note: Alexa Fluor-488-DNA complexed with 0.5
µg/mL (white bars), 2.5 µg/mL (grey bars), or 5 µg/mL (black
bars) of the respective cationic lipid was used, as indicated in
FIG. 8. Data are presented as the mean±SD.
While the average amount of DNA taken up/cell shows
wide variations between the different compounds (FIG. 8), all
compounds were able to deliver significant amounts of DNA
to virtually the entire cell population (FIG. 9). However, in
terms of gene therapy, simple DNA delivery to the cell is
insufficient. There are other cellular barriers, which must be
traversed.
GFP Expression Studies.
In order for the 'therapy' to be effective, the DNA must
escape from the endosome and enter the cell's nucleus, be
transcribed to a regulatory, non coding RNA (RNAi) or to
mRNA that is translated into its coded protein. Therefore, we
investigated the conjugate-assisted expression of an eGFP
DNA plasmid encoding for the green fluorescent protein
(GFP). CHO cells, which were successfully transfected, were
easily identified by their green fluorescence. Control experiments conducted with only the eGFP DNA plasmid (and no
lipid carrier) gave virtually no fluorescence. A gate or instrumental threshold was set based upon this low background
fluorescence. Fluorescence detected above this background
was considered a positive response.
FIG. 10. GFP Expression Results from Transfection Experiments.
CHO Kl cells were grown to approx. 50% sub-confluence
in 24-well plates, rinsed with medium and incubated for 4 hat
37° C. with 1 µg/mL eGFP DNA plasmid complexed with 0.5
µg/mL (white bars), 2.5 µg/mL (grey bars), or 5 µg/mL (black
bars) of the respective cationic lipid, as indicated above.
Medium was then changed, and cells were incubated for
another 24 h to allow for GFP plasmid expression. Cells were
detached by trypsin treatment and analyzed for GFP expression by FACS. Lipofectamine is denoted as LFA. The value
obtained with DNA plasmid only was subtracted from each
entry above (almost negligible).
The results obtained from the experiment described in FIG.
10 were analyzed using a gated channel to determine the

percentage of cells that expressed significant levels ofGFP as
compared with cells incubated with DNA plasmid only. A
gate was set just above the threshold measured with no DNA
plasmid and no conjugate added (almost negligible). All cells
which exhibited a fluorescence signal above that level were
considered positive. Data are presented as the mean±SD.
These are shown in FIG. 11.
The interpretation of the data in FIGS. 10 and 11 can be
quite subtle. For example, FIG. 10 relates the amount ofGFP
expression per cell and is a summary measurement of how
well the DNA 'message' was delivered, read and protein
(GFP) produced. While the magnitudes are different the relative trends are consistent with those observed in FIG. 8. In this
regard, DNA delivery correlated with GFP expression.
FIG. 11 revealed the% GFP positive cells observed in the
total cell population after the transfection experiment. This
information is a direct measure of transfection efficiency.
Using the 5 µg/mL dose for comparisons, 22 (38%), 25
(49%), and27 (40%) were all comparable to the LFA control
(41 % ) in terms of transfection efficiency. Both 23 (23%) and
24 (25%) gave lower values. The lone standout was tetraamine 26 (67%), which had over 50% higher transfection
efficiency than the LFA control (41 % ).
Cells treated with conjugate 23 at the high dose (5 µg/mL,
black bars in FIG. 9) gave 84% positive cells of the total cell
population remaining after the DNA uptake experiment;
whereas all the others (LFA, 22, and 24-28) gave typically
>94% positive cells. Using these data as benchmarks of DNA
import via each conjugate, the significantly lower % GFP
positive cells (23-67%) observed in FIG. 11 suggests that
intracellular processing and nuclear delivery of DNA also
depend on the structure of the cationic lipid.
A closer analysis of the data revealed just how important
these latter two parameters (i.e., intracellular processing and
nuclear delivery) are for successful gene delivery. For
example, although 26 was capable of delivering 3-fold more
DNA to the cell than the control LFA (black bars in FIG. 8: 26:
504; LFA: 158 a.u.), the relative GFP expression/cell was
only two fold higher in FIG. 10 (25 vs. 13 a.u.) and the% of
GFP positive cells was only 1.5 fold higher in FIG. 11 (67%
vs.41%).
It cannot be excluded that maximum GFP expression
occurs at varying time points post-transfection for the different compounds. Nevertheless, the data reflect an interesting
correlation between intracellular processing of internalized
DNA and the cationic lipid structure.
In summary, while a significant number of cells imported
the fluorescent DNA probe in the presence of the synthetic
conjugates (22-28), the amount of the DNA probe entering
each cell varied depending upon the conjugate used. The %
GFP positive cells of the total cell population roughly correlated with the GFP expression/cell. Cells with low % GFP
positive cells (FIG. 11: 23, 23%; 24, 25%) had low GFP
expression/cell (FIG.10: 23, 5; 24, 7). Cells with high% GFP
positive cells (FIG. 11: 26, 67%) had high GFP expression/
cell (FIG. 10: 26, 25). Indeed, the additional 'intracellular
barriers' associated with successful GFP expression (as
shown in FIG. 11 in terms of% GFP positive cells) seemed to
moderate the large differences seen in the earlier DNA delivery study (FIG. 8).
We theorized that 26 may be using the polyamine transporter, PAT, for cellular entry. Indeed, as shown in FIG. 12,
tetraamine 26 was shown to be a potent inhibitor of spermine
uptake (IC50 of approximately 10 µM) using a 14C-radiolabeled spermine competition assay. This observation implied
that 26 was able to compete for the polyamine recognition
sites on the cell surface (e.g., PAT). Therefore, it is possible
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that certain lipophilic polyamines, which present the correct
polyamine 'message', may be able to recognize and target
cells expressing high levels of polyamine transporters on their
cell surface (e.g., cancer cells, rapidly dividing tumors, etc.).
However, as shown in this report, delivery into the cell is just
one step in successful gene transfection. Nevertheless, the
findings disclosed herein are an important first step in developing 'smart' transfection agents.
Proof-of-principle for this novel therapeutic approach was
provided in the following journal article which utilized an
anti-cancer toxin that consisted of a chemical conjugate
between the human urokinase plasminogen activator and
saporin: Lipopolyamine Treatment Increases the Efficacy of
Intoxication with Saporin and an Anticancer Saporin Conjugate. Geden S. E.; Gardner R. A.; Fabbrini M. S.; Ohashi M.;
Phanstiel, IV, O.; Teter K. FEES J. 2007, 274, 4825-4836
(published onlineAug. 22, 2007). This journal article is incorporated herein by reference in its entirety.
We have also documented lipopolyamine-induced toxin
sensitization with two other saporin-based toxins: (i) FGFsaporin, a chemical conjugate between fibroblast growth factor and saporin; and (ii) the OKTlO immunotoxin which
consists of a chemical conjugate between saporin and an
antibody that recognizes the CD38 cancer antigen. DU145
human prostate cancer cells exposed to lipopolyamine 26 and
FGF-saporin were 85-fold more sensitive to intoxication than
cells incubated with FGF-saporin alone. The commercial
transfection agent Lipofectamine generated significant cellular sensitization to FGF-saporin as well. However, Lipafectamine also sensitized a non-target cell population (HeLa
cells, which do not express the FGF receptor) to FGF-saporin.
In contrast, HeLa cells exposed to lipopolyamine 26 and
FGF-saporin were no more sensitive to intoxication than cells
incubated with FGF-saporin alone. Our reagent thus exhibited a level of specificity that was not seen with Lipofectamine. We have also shown that Ramos human leukemia
cells exposed to lipopolyamine 26 and OKTlO are 100-fold
more sensitive to intoxication than cells incubated with
OKTlO alone. Ramos cells exposed to Lipofectamine and
OKTlO were no more sensitive to intoxication than cells
exposed to OKTlO alone. Collectively, these results demonstrate the utility of our lipopolyamine compounds over the
commercially available Lipofectamine reagent.
Conclusions.
This investigation demonstrated that the number and position of the positive charges along the polyamine scaffold
plays a key role in DNA delivery and in determining the
intracellular outcome of the DNA import event, i.e. the transfection efficiency. Although the Lipofectamine (LFA: 75% 4
and 25% 6 mixture) has five positive charges (presumably a
DNA delivery enliancing feature) in one of its components
(e.g., 4), it also has a neutral component DOPE 6 present,
which makes structural comparisons to this control difficult
beyond the dose to dose comparisons made above. Future
studies will look at the effect of neutral lipids (like 6) in terms
of transfection efficiency of polyamine-lipid conjugates.
Indeed, DOPE 6 has been shown to play a role in endosome
disruption and to facilitate transfection. 35
In addition, this paper presented the first study, which probed
the transfection phenomena with a PAT-selective homospermidine motif2 8 attached to a lipid cargo, e.g., 25. As expected
compound 25 showed a 3-fold enliancement in DNA delivery
over its butanediamine analogue 22. Unfortunately, the DNA
delivery enliancement observed with 25 seemed to be muted
by the latter steps of the transfection process (e.g., intracellular trafficking, nuclear delivery, etc). As a result, 25 had

only slightly higher transfection efficiency than 22 (e.g., 25
and 22 gave 49% and 38% GFP positive cells in FIG. 11,
respectively).
This phenomenon was also observed with the two
diamines, 27 and 22. Compound 27 showed greater than
4-fold enliancement in DNA delivery over its butanediamine
analogue 22. Evidently, moving the diamine 'message' further away from the lipid component enlianced the delivery
characteristics of the conjugate (FIG. 8). Again, this potential
delivery enliancement by 27 was tempered by the latter steps
of the transfection process. Alas, nearly identical transfection
efficiency was observed for 27 and 22 (40% and 38% GFP
positive cells in FIG. 11, respectively).
Clearly, cellular DNA delivery alone is insufficient for
successful transfection. Understanding how different
polyamine structures 21 ' 36 and neutral lipids like 635 enliance
the intracellular trafficking and nuclear delivery of plasmid
DNA is critical for the future design of efficient polyamine
transfection agents.
Experimental.
Materials.
Silica gel (32-63 µm) and chemical reagents were purchased from commercial sources and used without further
purification. All solvents were distilled prior to use. 1 H and
13
C NMR spectra were recorded at 300 and 75 MHz, respectively, unless otherwise noted. TLC solvent systems are based
on volume % and NH4 0H refers to concentrated aqueous
NH4 0H. High-resolution mass spectrometry was performed
at the University of Florida Mass Spectrometry facility.
Materials and Methods
ULYSISAlexaFluor-488 (Molecular Probes) was used for
labeling of DNA as recommended by the manufacturer. All
fine chemicals were from Sigma. Lipofectamine 2000 was
purchased from Invitrogen. Wild-type Chinese hamster ovary
cells (CHO-Kl) were obtained from the ATCC (Manassas,
Va., USA). CH 0 cells were routinely cultured in F 12K nutrient mixture supplemented with 10% (v/v) fetal calf serum, 2
mM L-glutamine, 100 units/ml penicillin, and 100 µg/ml
streptomycin (growth medium) in a humidified 5% C0 2 , 37°
C. incubator.
DNA uptake studies. AlexaFluor-488 labeled DNA with or
without cationic lipid was mixed in serum-free F12K and
added to extensively rinsed cells grown in 24-well plates.
Cells were then incubated for 4 hat 37° C. After removal of
the incubation medium and rinsing with PBS, cells were
detached with trypsin followed by extensive washing with
ice-cold PBS, 1% (w/v) bovine serum albumin (BSA) to
remove non-specific fluorescence. Finally, cells were suspended in PBS, 1% BSA and analyzed for DNA uptake by
flow cytometry on a FACSCalibur (BD Biosciences) operated
by Cell-Quest software. Cells remained viable with all compounds tested, including 28.
GFP transfection experiments---eGFP encoding DNA
plasmid with or without cationic lipid was mixed in F 12K and
incubated with pre-rinsed, sub-confluent cells in 24-well
plates for 4 h, followed by another incubation period of 24 h
in growth medium. Cells were then washed with PBS,
detached by trypsin treatment, dissolved in PBS, 1% BSA,
and analyzed by FACS for GFP expression. Note: severe
toxicity was noted for compound 28 after the 24 h incubation
period.
Biological Studies.
CHO cells were grown in RPMI medium supplemented
with 10% fetal calf serum, glutamine (2 mM), penicillin (100
U/mL), streptomycin (50 µg/mL). Cells were grown at 37° C.
under a humidified 5% C0 2 atmosphere. Aminoguanidine (2
mM) was added to the culture medium to prevent oxidation of
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the drugs by the enzyme (bovine serum amine oxidase)
present in calf serum. Trypan blue staining was used to determine cell viability before the initiation of a cytotoxicity
experiment. L1210 cells in early to mid log-phase were used.
Cell growth was assayed in sterile 96-well microtiter plates
(Becton-Dickinson, Oxnard, Calif., USA). CHO cells were
plated at 2e 3 cells/mL. Drug solutions (10 µL per well) of
appropriate concentration were added after an overnight
incubation for the CHO cells. After exposure to the drug for
4S hr, cell growth was determined by measuring formazan
formation from 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium using a Titertek Multiskan MCC/340 microplate
reader for absorbance (540 nm) measurements. 37 These
experiments allowed for a quick assessment of conjugate
cytotoxicity and facilitated determination of the proper dosing for the latter transfection and delivery experiments.
3,4-Bis-octadec-9-enyloxy-benzaldehyde (Sa):
To a solution of oleyl bromide (1.S g, 5.4 mmol) in cyclohexanone (20 ml) was added protocatachualdehyde (0.341 g,
2.5 mmol), potassium carbonate (1.02 g, 7.4 mmol) and
potassium iodide (0.05 g, 0.3 mmol). The suspension was
stirred at 100° C. for 1S hours under nitrogen. Due to the light
sensitivity of the oleyl bromide the flask was covered in
aluminum foil. TLC (10% MeOH/CHCl 3 ) showed the reaction was complete. The hot reaction mixture was filtered to
remove some of the particulates and the solvent was removed
in vacuo. The residue was dissolved in CHCl 3 (100 mL) and
washed with water (2x75 mL). The CHCl 3 layer was dried
over anhydrous sodium sulphate, filtered and the solvent
removed in vacuo to give a dark yellow oil. The oily residue
was purified by flash colunm chromatography (5% EtAc/
hexane) to yield the product Sa as a white solid (1.0S g, 69% ),
Rf=0.3 (5% EtAc/hexane). 1 H NMR (CDCl 3 ) d 9.SO (s, lH,
CHO), 7.37 (m, 2H,phenyl), 6.93 (d, lH,phenyl), 5.33 (t, 4H,
olefinic), 4.06 (t, 2H, OCH 2 ), 4.04 (t, 2H, OCH 2 ), 2.01 (m,
SH, CH 2 C=C), 1.S5 (m, 4H, CH 2 CH 2 0), 1.50-1.lS (m, 44H,
22xCH 2 ), O.SS (t, 6H, CH 3 ); rrc NMR (CDCl 3 ) d 191.00,
155.34, 149.95, 130.14, 130.12, 129.97, 126.79, 111.S9,
111.04, 69.36, 32.29, 30.16, 29.92, 29.90, 29.SS, 29.72,
29.64, 29.62, 29.44, 29.36, 27.60, 26.37, 26.34, 23.09, 14.53;
HRMS (FAB): theory for C43 H75 0 3 (M +1), 639 .5716; found
(M+l), 639.5755.Anal. (C43 H740 3 ): C, H.
3,4-Bis-octadec-9-enyloxy-benzoic acid (Sc):
To a solution of oleyl bromide (1.S g, 5.4 mmol) in cyclohexanone (20 ml) was added ethyl 3,4-dihydroxybenzoate 7b
(0.45 g, 2.5 mmol), potassium carbonate (1.02 g, 7.4 mmol)
and potassium iodide (0.05 g, 0.3 mmol). The suspension was
stirred at 100° C. for 1S hours under nitrogen. Due to the light
sensitivity of the oleyl bromide the flask was covered in
aluminum foil. The hot reaction mixture was filtered to
remove some of the particulates and the solvent was removed
in vacuo. The residue containing ester Sb was dissolved in a
solution of ethanol (20 mL) containing potassium hydroxide
(O.S g, 20 mmol) and refluxed for 4 h. The hot reaction
mixture was added to water (30 mL) and acidifying with IM
HCI to pH 1 resulted in the precipitation of a white solid. The
solid Sc was filtered off and washed several times with water.
The crude acid was re-crystallized from ethanol (10 mL) to
give the product Sc as a white solid (1.14 g, 70% ); 1 H NMR
(500 MHz, CDCl 3 ) d 7.73 (dd, lH, phenyl), 7.5S (d, lH,
phenyl), 6.S9 (d, lH, phenyl), 5.35 (t, 4H, olefinic), 4.05 (2xt,
4H, 2xOCH 2 ), 2.01 (m, SH, CH 2 C=C), 1.S5 (m, 4H, C
H 2 CH 2 0), 1.4S (quin, 4H, 2xCH 2 ), 1.41-1.19 (m, 40H,
20xCH 2 ), O.SS (t, 6H, CH 3 ).

Acid chloride (Sd):
See Compound 20 for experimental details.
(4-Amino-butyl)-carbamic acid tert-butyl ester (9):
1,4-Diaminobutane (4.4 g, 0.05 mo!) was dissolved in a
solution oftriethylamine and methanol (10% TEA in MeOH,
110 mL). A solution of di-tert-butyl dicarbonate (3.63 g,
0.017 mo!) in methanol (10 mL) was added dropwise to this
mixture with vigorous stirring. The mixture was stirred at RT
overnight. The tert-butoxy-carbonylation was complete as
evidenced by TLC (4% NH4 0H/MeOH). The excess 1,4diaminobutane, methanol and TEA were removed in vacuo to
yield an oily residue that was dissolved in dichloromethane
(100 mL) and washed with a solution of sodium carbonate
(10% aq, 2xlOOmL). The organic layer was dried over anhydrous sodium sulfate, filtered, the solvent removed in vacuo
and the oily residue purified by flash colunm chromatography
(1:10:S9 NH4 0H:MeOH:CHCl 3 ) to give the product 9 as a
clear oil (2.23 g, 71%), Rf=0.3S (1:10:S9 NH4 0H:MeOH:
CHCl 3 ). 1 HNMR(CDCl 3 )d4.72 (brs, lH, NHCO), 3.12 (q,
2H, CH 2 ), 2.70 (t, 2H, CH 2 ), 1.57-1.30 (m, 13H, 2xCH 2 ,
3xCH3 ).
[4-(3-Cyano-propylamino )-butyl]-carbamic acid tert-butyl
ester (10):
To a solution of the BOC protecteddiamine 9 (2.10 g, 0.01
mo!) in anhydrous acetonitrile (50 mL) was added potassium
carbonate (5.14 g) and the suspension was stirred at RT for 10
minutes. A solution of 4-bromobutyronitrile (1.65 g, 0.01
mo!) in acetonitrile (25 mL) was added and the resulting
mixture stirred at 50° C. for 24 hours. TLC (1:10:S9 NH4 0H:
MeOH:CHCl 3 ) showed that the reaction was 95% complete.
The mixture was filtered to remove most of the inorganic salts
and the acetonitrile was removed in vacuo to give a solid/oily
residue that was purified by flash colunm chromatography
(1:5:94 NH4 0H:MeOH:CHCl 3 ) to yield the product 10 as a
clear oil (1.74 g, 61 %), Rf=0.5 (1:10:S9 NH4 0H:MeOH:
CHCl 3 ); 1 HNMR(CDCl 3 ) d4.79 (brs, lH, NHCO), 3.12 (q,
2H, CH 2 ), 2.74 (t, 2H, CH 2 ), 2.60 (t, 2H, CH 2 ), 2.46 (t, 2H,
CH 2 ), 1.Sl (quin, 2H, CH 2 ) 1.57-1.37 (m, 13H, 2xCH 2 ,
3xCH3 ).
(4-tert-Butoxycarbony!amino-butyl )-(3-cyano-propyl )-carbamic acid tert-butyl ester (11):
The amino-nitrile 10 (1.74 g, 6.S mmol) was dissolved in a
solution oftriethylamine and methanol (10% TEA in MeOH,
40 mL). A solution of di-tert-butyl dicarbonate (3.63 g, 0.017
mo!) in methanol (20 mL) was added dropwise to this mixture
with vigorous stirring. The mixture was stirred at it overnight.
TLC (1:10:S9 NH4 0H:MeOH:CHCl 3 ) showed the tert-butoxycarbonylation was complete. The methanol and TEA
were removed in vacuo to yield an oily residue that was
dissolved in dichloromethane (100 mL) and washed with a
solution of sodium hydroxide (2.5 M, 3x30 mL) and water
(2x30 mL). The organic layer was dried over anhydrous
Na 2 S04 , filtered, the solvent removed in vacuo and the oily
residue purified by flash colunm chromatography (40% EtAc/
hexane) to give the product 11 as a clear oil (2.10 g, S7% ),
Rf=0.45 ( 40% EtAc/hexane); 1 H NMR (CDCl 3 ) d 4.60 (br s,
lH, NHCO), 3.2S (t, 2H, CH 2 ), 3.14 (m, 4H, 2xCH 2 ), 2.35 (t,
2H, CH 2 ), 1.SS (quin, 2H, CH 2 ), 1.5S-1.2S (m, 22H, 2xCH 2 ,
6xCH 3 ).
( 4-Amino-butyl)-( 4-tert-butoxycarbonylamino-butyl)-carbamic acid tert-butyl ester (12):
The nitrile 11 (2.00 g, 5.6 mmol) was dissolved in ethanol
(100 mL). NH4 0H (10 mL) and Raney nickel (S g) were
added and ammonia gas was bubbled through the solution for
20 minutes at 0° C. The suspension was hydrogenated at 50
parr for 24 hours. Air was bubbled through the solution and
the Raney nickel was removed by filtering through a sintered
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glass funnel keeping the Raney nickel residue moist at all
nitrogen overnight. 1H NMR showed the reaction to be comtimes. The ethanol and NH40H were removed in vacuo and
plete when there was no aldehyde peak present. The solvent
was removed in vacuo and the crude imine dissolved in
the oily residue dissolved in CH 2Cl 2 and washed with 10%
aq, Na 2C03 (3x50 mL). The organic layer was dried over
CH 2CliMeOH (1:1, 10 mL). The solution was cooled to 0°
anhydrous Na 2S04, filtered and the solvent removed in vacuo 5 C. and NaBH4 (60 mg, 1.5S mmol) was added in 15 mg
portions over 30 minutes. TLC (10% EtAc/hexane) showed
to give the product 12 as a clear oil without further purification (1.92 g, 95% ), Rf=0.4(1:10:S9 NH40H:MeOH:CHCl 3);
the reaction to be complete after stirring overnight. The sol1H NMR (CDCl ) d 4.65 (br s, lH, NHCO), 3.14 (m, 6H,
vent was removed in vacuo and the crude oil dissolved in
3
CH 2Cl 2 (50 mL) and washed with sodium carbonate (10% aq,
3xCH2), 2.69 (t, 2H, CH 2), 2.35 (t, 2H, CH 2), 1.5S-1.26 (m,
1o 3 x40 mL). The CH 2Cl 2 layer was dried over N a 2C0 3, filtered,
26H, 4xCH 2, 6xCH 3).
the solvent removed in vacuo and the oily residue purified by
(4-tert-Butoxycarbonylamino-butyl )-{ 4-[tert-butoxycarboflash colunm chromatography (4% MeOH/CHCl 3) to give the
ny1-(3-cyano-propy!)-amino]-butyI}-carbamic acid tert-buproduct 15 as a clear oil (O.lS g, 7S%), Rf=0.2 (3% MeOH/
ty lester (13):
To a solution the amine 12 (1.32 g, 3.6S mmol) in anhyCHCl 3). 1H NMR (500 MHz, CDCl 3) d 6.S5 (s, lH, aryl),
drous acetonitrile (20 mL) was added potassium carbonate 15 6.SO (m, 2H, aryl), 5.34 (t, 4H, olefinic), 4.7S (br s, lH,
(1.7 g) and the suspension was stirred at rt for 10 minutes. A
NHCO), 3.97 (q, 4H, OCH 2), 3.69 (s, 2H, benzylic), 3.13 (m,
solution of 4-bromobutyronitrile (0.54 g, 3.6S mmol) in
2H, CH 2) 2.63 (t, 2H, CH 2NH), 2.01 (m, SH, CH 2C=C), 1.SO
acetonitrile (10 mL) was added and the resulting mixture
(m, 4H, CH 2CH 20), 1.55 (m, 4H), 1.49-1.12 (m, 57H,
stirred at 50° C. under nitrogen for 24 hours. TLC (1:10:S9
24xCH2, 3XCH3), O.S9 (t, 6H, CH3); 13 C NMR (CDCl3) d
NH40H:MeOH:CHCl 3) showed the reaction was 95% com- 20 156.17, 149.34, 14S.29, 133.15, 130.11, 130.00, 120.67,
114.lS, 114.0S, 79.23, 69.69, 69.52, 54.12, 49.22, 40.SO,
plete. The mixture was filtered to remove most of the inorganic salts and the acetonitrile was removed in vacuo to give
32.2S, 30.16, 29.92, 29.S2, 29.71, 29.67, 2S.Sl, 2S.27, 27.6S,
a solid/oily residue. The oil was dissolved in anhydrous THF
27.60, 26.44, 23.09, 14.54; Anal. (C 52 H 94N 20 4): C, H, N.
N 1-(3,4-Bis-octadec-9-enyloxy-benzyl)-octane- l ,S-diamine
(70 mL). A solution of di-tert-butyl dicarbonate (1.21 g, 5.5
mmol) in THF (20 mL) was added dropwise to this mixture 25 (16):
with vigorous stirring. The mixture was stirred at RT overTo a vigorously stirred solution of diaminooctane (0.23 g,
night. TLC (1:10:S9 NH40H:MeOH:CHCl3) showed the
1.56 mmol, 5 equiv) in CH 2CliMeOH (3: 1, 5 mL) was added
tert-butoxycarbonylation was complete. The THF was
a solution of the aldehyde Sa (0.20 g, 0.33 mmol) in CH 2Cl 2/
removed in vacuo to yield an oily residue that was dissolved
MeOH (3:1, 5 mL), dropwise over 1 hour. The resulting
in dichloromethane (100 mL) and washed with a solution of 30 mixture was stirred at RT under an atmosphere of nitrogen
overnight. NMR showed the reaction to be complete when
sodium hydroxide (2.5 M, 3x30 mL). The organic layer was
there was no aldehyde peak present in the NMR spectrum.
dried over anhydrous sodium sulfate, filtered, the solvent
The solvent was removed in vacuo and the crude imine disremoved in vacuo and the oily residue purified by flash colsolved in CH 2Cl 2/MeOH (1:1, 10 mL). The solution was
unm chromatography (CHCl 3/MeOH 99: 1) to give the product 13 as a clear oil (1.46 g, 75%), Rf=0.5 (CHCl 3/MeOH 35 cooled to 0° C. and sodium borohydride (60 mg, 1.5S mmol)
was added in 15 mg portions over 30 minutes. TLC (10%
99:2); 1H NMR (CDCl 3) d4.63 (bs, lH, NHCO), 3.2S (t, 2H,
CH 2), 3.14 (m, SH, 4xCH 2), 2.64 (t, 2H, CH 2), 1.SS (quin,
EtAc/hexane) showed the reaction to be complete after stir2H, CH 2), 1.5S-1.35 (m, 35H, 4xCH 2, 9xCH 3).
ring overnight. The solvent was removed in vacuo and the
crude solid dissolved in CH 2Cl 2 (50 mL) and washed with
{4-[(4-Amino-butyl)-tert-butoxycarbonyl-amino ]-butyl}(4-tert-butoxycarbonyl-amino-butyl)-carbamic acid tert-bu- 40 sodium carbonate (10% aq, 3x40 mL ). The CH 2Cl 2 layer was
tyl ester (14):
dried over sodium sulfate, filtered, the solvent removed in
The nitrile 13 (1.33 g, 2.5 mmol) was dissolved in ethanol
vacuo and the solid residue purified by flash colunm chromatography (1:10:S9 NH40H:MeOH:CHCl 3) to give the prod(100 mL). NH40H (10 mL) and Raney nickel (6 g) were
added and ammonia gas was bubbled through the solution for
uct 16 as a white solid (0.15 g, 63%), Rf=0.5 (1:10:S9
20 minutes at 0° C. The suspension was hydrogenated at 50 45 NH40H:MeOH:CHCl 3). 1H NMR (CDCl 3) d 6.S5 (s, lH,
psi for 24 hours. Air was bubbled through the solution and the
aryl), 6.SO (m, 2H, aryl), 5.34 (t, 4H, olefinic), 3.97 (q, 4H,
Raney nickel was removed by filtering through a sintered
OCH 2), 3.69 (s, 2H, benzylic), 2.67 (t, 2H, CH 2NH 2), 2.60 (t,
glass funnel keeping the Raney nickel residue moist at all
2H, CH2NH2), 2.01 (m, SH, CH2C=C), r:so (m, 4H, c
times. The ethanol and NH40H were removed in vacuo and
H2CH;l}), 1.54-1.lS (m, 56H, 2SxCH 2), O.SS (t, 6H, CH 3);
the oily residue dissolved in CH 2Cl 2 and washed with sodium 50 tic NMR (CDCl 3) d 149.31, 14S.20, 133.55, 130.11, 130.00,
carbonate (10%, aq, 3x50 mL). The organic layer was dried
120.59, 114.14, 114.07, 69.70, 69.50, 54.24, 49.S3, 42.60,
over anhydrous sodium sulphate, filtered and the solvent
34.20, 32.2S, 30.46, 30.16, 29.92, 29.Sl, 29.71, 29.67, 27.73,
removed in vacuo. The oil was purified by flash column
27.60, 27.22, 26.44, 23.0S, 14.53; HRMS (FAB): theory for
chromatography (1:10:S9 NH40H:MeOH:CHCl3) to give
C 51 H95 N 20 2 (M+l), 767.7394; found (M+l), 767.7377.
the product 14 as a clear oil (O.S5 g, 64%), Rf=0.5 (1:10:S9 55 Anal. (C 51 H94N 20 2.0.3H20): C, H, N.
2-{ 2-[2-(3,4-Bis-octadec-9-enyloxy-benzylamino )-ethoxy]NH40H:MeOH:CHCl 3). 1H NMR (CDCl 3) d 4.65 (s, lH,
ethoxy }-ethylamine (17):
NHCO), 3.15 (m, !OH, 5xCH2), 2.70 (t, 2H, CH 2NH 2), 1.5S1.39 (m, 39H, 6xCH 2, 9xCH 3); HRMS (FAB): theory for
To a vigorously stirred solution of diaminodioxaoctane
C 27 H55 N40 6 (M+l), 531.4122; found (M+l), 531.4111;
(0.23 g, 1.56 mmol, 5 equiv) in CH 2Cl 2/MeOH (3:1, 5 mL)
Anal. Calcd (C 27 H54N40 6 0.1H 20): C, H, N.
60 was added a solution of the aldehyde Sa (0.20 g, 0.33 mmol)
[4-(3 ,4-Bis-octadec-9-enyloxy-benzy!amino)-butyl ]-carin CH 2Cl 2/MeOH (3:1, 5 mL), dropwise over 1 hour. The
resulting mixture was stirred at rt under an atmosphere of
bamic acid tert-butyl ester (15):
To a vigorously stirred solution of the amine 9 (0.071 g,
nitrogen overnight. NMR showed the reaction to be complete
0.3S mmol, 1.2 equiv) in CH 2CliMeOH (3:1, 5 mL) was
when there was no aldehyde peak present in the NMR specadded a solution of the aldehyde Sa (0.20 g, 0.33 mmol) in 65 trum. The solvent was removed in vacuo and the crude imine
dissolved in CH 2CVMeOH (1:1, 10 mL). The solution was
CH 2Cl 2/MeOH (3:1, 5 mL), dropwise over 20 minutes. The
resulting mixture was stirred at it under an atmosphere of
cooled to 0° C. and NaBH4 (60 mg, 1.5S mmol) was added in
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15 mg portions over 30 minutes. TLC (10% EtAc/hexane)
showed the reaction to be complete after stirring overnight.
The solvent was removed in vacuo and the crude oil dissolved
in CH 2 Cl 2 (50 mL) and washed with sodium carbonate (10%
aq, 3x40 mL). The CH 2 Cl 2 layer was dried over anhydrous
Na 2 S04 , filtered, the solvent removed in vacuo and the oily
residue purified by flash column chromatography (1:10:S9
NH4 0H:MeOH:CHCl 3 ) to give the product 17 as a clear oil
(0.16S g, 70%), Rf=0.45 (1:10:S9 NH4 0H:MeOH:CHCl 3 ).
1
HNMR(CDCl 3 ) d6.S7 (s, lH, aryl), 6.Sl (m, 2H, aryl), 5.34
(t, 4H, olefinic), 3.97 (q, 4H, OCH 2 ), 3.72 (s, 2H, benzylic),
3.61 (m, 6H, OCH 2 ), 3.61 (t, 2H, OCH 2 ), 2.S6 (t, 2H, C
H 2 NH 2 ), 2.Sl (t, 2H, CH 2 NH 2 ), 2.01 (m, SH, CH 2 C=C),
I.SO (m, 4H, CH 2 CH 2 0)-;-1.54-1.17 (m, 44H, 22xCH 2 ), O.S9
(t, 6H, CH 3 ); 1TC NMR (CDCl 3 ) d 149.31, 14S.25, 133.11,
130.09, 129.99, 120.73, 114.26, 114.07, 73.57, 70.S5, 70.57,
70.52, 69.69, 69.51, 54.02, 4S.93, 42.01, 32.2S, 30.15, 29.91,
29.SO, 29.70, 29.67, 27.59, 26.45, 26.42, 23.07, 14.53;
HRMS (FAB): theory for C49 H91 N 2 0 4 (M+l), 771.6979;
found (M+l), 771.6995; Anal. (C49 H90 N 2 0 4 ): C, H, N.
(4-{[ 4-(3,4-Bis-octadec-9-enyloxy-benzylamino )-butyl]tert-butoxycarbonyl-amino }-butyl)-carbamic acid tert-butyl
ester (IS):
To a vigorously stirred solution of the amine 12 (0.135 g,
0.3S mmol, 1.2 equiv) in CH 2 CliMeOH (3:1, 5 mL) was
added a solution of the aldehyde Sa (0.20 g, 0.33 mmol) in
CH 2 Cl 2 /MeOH (3:1, 5 mL), dropwise over 20 minutes. The
resulting mixture was stirred at RT under an atmosphere of
nitrogen overnight. NMR showed the reaction to be complete
when there was no aldehyde peak present in the NMR spectrum. The solvent was removed in vacuo and the crude imine
dissolved in CH 2 Cl 2 /MeOH (1:1, 10 mL). The solution was
cooled to 0° C. and sodium borohydride (60 mg, 1.5S mmol)
was added in 15 mg portions over 30 minutes. TLC (10%
EtAc/hexane) showed the reaction to be complete after stirring overnight. The solvent was removed in vacuo and the
crude oil dissolved in CH 2 Cl 2 (50 mL) and washed with
sodium carbonate (10% aq, 3x40 mL ). The CH 2 Cl 2 layer was
dried over sodium sulphate, filtered, the solvent removed in
vacuo and the oily residue purified by flash column chromatography (3% MeOH/CHCl 3 ) to give the product 1Sas a clear
oil (0.24 g, 7S%), Rf=0.3 (3% MeOH/CHCl 3 ). 1 H NMR
(CDCl 3 ) d 6.S5 (s, lH, aryl), 6.SO (m, 2H, aryl), 5.34 (t, 4H,
olefinic), 4.60 (brs, lH, NHCO), 3.97 (q, 4H, OCH 2 ), 3.69 (s,
2H, benzylic), 3.13 (m, 6H, CH 2 ) 2.63 (t, 2H, CH 2 NH), 2.01
(m, SH, CH 2 C=C), 1.SO (m, 4H, CH 2 CH 2 0), 1-:67-1.15 (m,
70H, 26xCH 2 , 6xCH 3 ), O.S9 (t, 6H, CH 3 ); 13 C NMR (CDCl 3 )
d 156.17, 155.71, 149.33, 14S.25, 133.31, 130.11, 130.00,
120.62, 114.15, 114.0S, 79.45, 69.70, 69.51, 54.13, 49.42,
47.34, 46.S9, 40.5S, 32.2S, 30.14, 29.91, 29.SO, 29.70, 29.67,
2S.S5, 2S.79, 27.79, 27.70, 27.59, 26.42, 23.07, 14.53;
HRMS (FAB): theory for C 61 H 112N 3 0 6 (M+l), 9S2.S551;
found (M+l), 9S2.S510; Anal. (C 61 HrnN3 0 6 ): C, H, N.
(4-{[ 4-(3,4-Bis-octadec-9-enyloxy-benzylamino )-butyl]tert-butoxycarbony I-amino }-butyI)-(4-tert-butoxycarbonylamino-butyl)-carbamic acid tert-butyl ester (19):
To a vigorously stirred solution of the amine 14 (0.20 g,
0.3S mmol, 1.2 equiv) in CH 2 CliMeOH (3:1, 5 mL) was
added a solution of the aldehyde Sa (0.20 g, 0.33 mmol) in
CH 2 Cl 2 /MeOH (3:1, 5 mL), dropwise over 20 minutes. The
resulting mixture was stirred at RT under an atmosphere of
nitrogen overnight. NMR showed the reaction to be complete
when there was no aldehyde peak present in the spectrum.
The solvent was removed in vacuo and the crude imine dissolved in CH 2 Cl 2 /MeOH (1:1, 10 mL). The solution was
cooled to 0° C. and sodium borohydride (60 mg, 1.5S mmol)
was added in 15 mg portions over 30 minutes. TLC (10%

EtAc/hexane) showed the reaction to be complete after stirring overnight. The solvent was removed in vacuo and the
crude oil dissolved in CH 2 Cl 2 (50 mL) and washed with
sodium carbonate (10% aq, 3x40 mL ). The CH 2 Cl 2 layer was
dried over sodium sulphate, filtered, the solvent removed in
vacuo and the oily residue purified by flash column chromatography (3% MeOH/CHCl 3 ) to give the product 19 as a clear
oil (0.319 g, SS%), Rf=0.25 (3% MeOH/CHCl 3 ). 1 H NMR
(CDCl 3 ) d 6.S5 (s, lH, aryl), 6.SO (m, 2H, aryl), 5.34 (t, 4H,
olefinic), 4.60 (brs, lH, NHCO), 3.97 (q, 4H, OCH 2 ), 3.70 (s,
2H, benzylic), 3.14 (m, lOH, 5xCH 2 ) 2.64 (t, 2H, CH 2 NH),
2.01 (m, SH, CH 2 C=C), 1.SO (m, 4H, CH 2 CH 2 0), 1.39-1.14
(m, S3H, 2SxCH 2 , 9xCH 3 ), O.S9 (t, 6H, CH 3 ); 13 C NMR
(CDCl 3 ) d 156.12, 155.69, 149.33, 14S.25, 133.2S, 130.10,
129.99, 120.61, 114.14, 114.07, 79.40, 69.69, 69.50, 54.15,
49.47, 47.24, 46.9S, 40.57, 32.27, 30.14, 29.90, 29.SO, 29.69,
29.66, 2S.S5, 2S.79, 27.77, 27.5S, 26.44, 23.07, 14.53;
HRMS (FAB): theory for C 70 H 129 N4 0 8 (M+l), 1153.9S10;
found (M+l), 1153.9S40;Anal. Calcd (C 70 H 128N4 0 8 ): C, H,
N.
(4-{ [4-(3,4-Bis-octadec-9-enyloxy-benzoylamino)-butyl]tert-butoxycarbonyl-amino }-butyl)-carbamic acid tert-butyl
ester (20):
A solution of 3,4-Bis-octadec-9-enyloxy-benzoic acid Sc
(0.2 g, 0.31 mmol) in 2:1 dichloromethane/benzene (15 mL)
was stirredat0° C. for lOmin.AnhydrousDMF (2 drops) and
oxalyl chloride (0.3 mL) were added in sequence and the
mixture was stirred for 1 hat 0° C. The solution was concentrated in vacuo to give the crude acid chloride, Sd. Crude Sd
was dissolved in CH 2 Cl 2 (10 mL) and added dropwise to a
solution of the amine 12 (0.132 g, 0.37 mmol, 1.2 equiv.)
dissolved in CH 2 Cl 2 (10 mL) and lMNaOH (10 mL) thathad
been cooled to 0° C. for 15 minutes. The reaction was stirred
overnight under N 2 at room temperature. The water layer was
separated off. The CH 2 Cl 2 layer was washed with Na 2 C0 3
(10% aq. 3x20 mL), dried over Na2 S04 , filtered, removed in
vacuo and the oily residue purified by flash column chromatography (30% EtAc/hexane) to give the product 20 as a clear
oil (0.261 g, S6%), Rf=0.25 (30% EtAc/hexane); 1 H NMR
(500 MHz, CDCl 3 ) d 7.50-7.20 (m, 2H, phenyl), 6.90 (br s,
0.5H, NHCO), 6.Sl (d, lH,phenyl), 6.41(brs,0.5H, NHCO),
5.35 (t, 4H, olefinic), 4.6S (m, lH, NHCO), 3.99 (2t, 4H,
2xOCH 2 ), 3.44 (m, 2H, CH 2 ), 3.11(m,6H, 3xCH2 ), 2.00 (m,
SH, CH 2 C=C), 1.79 (m, 4H, CH 2 CH 2 0), 1.53-1.17 (m, 70H,
26xCH 2 , 6xCH 3 ), O.SS (t, 6H;-CH 3 ); 13 C NMR (CDCl 3 ) d
167.32, 156.lS, 151.S4, 14S.9S, 130.11, 130.09, 127.32,
113.02, 112.39, 79.62, 79.32, 69.52, 69.36, 47.09, 40.49,
39.92, 32.26, 30.13, 29.S9, 29.76, 29.6S, 29.65, 29.62, 29.59,
29.50, 2S.S4, 2S.77, 27.79, 27.5S, 26.3S, 26.36, 23.06, 14.51;
HRMS (FAB): theoryforC 61 H 109 N 3 0 7 (M+Na), 101S.S15S;
found (M+Na), 101S.S123; Anal. (C 61 H 109 N 3 0 7 ): C, H, N.
(4-{ [4-(3,4-Bis-octadec-9-enyloxy-benzoylamino)-butyl]tert-butoxycarbonyl-amino }-buty!)-(4-tert-butoxycarbonylamino-buty l )-carbamic acid tert-butyl ester (21):
A solution of 3,4-Bis-octadec-9-enyloxy-benzoic acid Sc
(0.2 g, 0.31 mmol) in 2:1 dichloromethane/benzene (15 mL)
was stirredat0° C. for lOmin.AnhydrousDMF (2 drops) and
oxalyl chloride (0.3 mL) were added in sequence and the
mixture was stirred for 1 hat 0° C. The solution was concentrated in vacuo to give the crude acid chloride Sd. The acid
chloride Sd was dissolved in CH 2 Cl 2 (10 mL) and added
dropwise to a solution of the amine 14 (0.195 g, 0.37 mmol,
1.2 equiv.) dissolved in CH 2 Cl 2 (10 mL) and IM NaOH (10
mL) that had been cooled to 0° C. for 15 minutes. The reaction
was stirred overnight under N 2 at room temperature. The
water layer was separated off. The CH 2 Cl 2 layer was washed
with Na 2 C0 3 (10% aq. 3x20 mL), dried over Na2 S04 , fil-
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tered, removed in vacuo and the oily residue purified by flash
colunm chromatography (30% EtAc/hexane) to give the
product 21 as a clear oil (0.295 g, S3% ), Rf=0.20 (30% EtAc/
hexane); 1 H NMR (500 MHz, CDC1 3 ) d 7.42-7.20 (m, 2H,
phenyl), 6.S2 (br s, 0.5H, NHCO), 6.SO (d, lH, phenyl), 6.39
(br s, 0.5H, NHCO), 5.35 (t, 4H, olefinic), 4.65 (m, lH,
NHCO), 3.99 (2xt, 4H, 2xOCH 2 ), 3.42 (m, 2H, CH 2 ), 3.13
(m, !OH, 5xCH 2 ), 2.00 (m, SH, CH 2 C=C), 1.79 (m, 4H, C
H 2 CH 2 0), 1.53-1.17 (m, S3H, 2SxCH 2 , 9xCH 3 ), O.SS (t, 6H,
CH 3 ); 13 C NMR (CDC1 3 ) d 167.35, 156.16, 155.73, 151.SS,
14S.99, 130.13, 130.11, 127.37, 113.05, 112.41, 79.54,
69.54, 69.3S, 47.03, 40.5S, 39.97, 32.27, 30.14, 29.90, 29.77,
29.69, 29.66, 29.63, 29.60, 29.51, 2S.S5, 2S.79, 27.7S, 27.59,
26.40, 26.37, 23.07, 14.53; HRMS (FAB): theory for
C 70 H 126 N4 0 9 (M+Na), 11S9.9407; found (M+Na),
11S9.9365; Anal. (C 70 H 126N4 0 8 ): C, H, N.
N 1 -(3,4-Bis-octadec-9-enyloxy-benzyl)-butane- l ,4-diamine, dihydrochloride salt (22):
A concentrated solution of the amine 15 (0.15S g, 0.19
mmol) in ethyl acetate was added cooled to 0° C. A total of 4
mL of a freshly prepared saturated solution of HCl in ethyl
acetate was added dropwise and the solution stirred for 1 hat
room temperature during which time a white precipitate
formed. The ethyl acetate was removed in vacuo and the
residue co-evaporated with ethyl acetate and chloroform to
give the product 22 as an off white powder (0.15 g, 9S%); 1 H
NMR (500 MHz, CDC1 3 ) d 9.50 (br s, 2H, R 2 WH 2 ), S.22 (br
s, 3H, RWH 3 ), 7.24 (s, lH, aryl), 7.05 (d, lH, aryl), 6.S2 (d,
lH, aryl), 5.34 (m, 4H, olefinic), 4.02 (q, 4H, OCH 2 ), 3.93 (t,
2H, benzylic), 3.07 (m, 2H, CH 2 )2.Sl (m, 2H, CH 2 ), 2.01 (m,
SH, CH 2 C=C), 1.95 (m, 2H, CH 2 ), 1.S5 (m, 2H, CH 2 ), 1.7S
(m, 4H, CH 2 CH 2 0), 1.45 (m, 4H, 2xCH 2 ), 1.3S-1.20 (m,
40H, 20xCH 2 ), O.S9 (t, 6H, CH 3 ); 13 C NMR (300 MHz,
CDC1 3 ) d 150.00, 149.37, 130.12, 130.09, 129.95, 122.5S,
115.Sl, 113.49, 69.63, 69.3S, 51.44, 51.06, 45.SO, 39.63,
32.29, 30.24, 30.21, 30.16, 30.00, 29.93, 29.71, 27.61, 26.63,
26.49, 24.S3, 23.75, 23.0S, 14.54; HRMS (FAB): theory for
C47 H 37N 2 0 2 (M+l), 711.676S; found (M+l), 711.6S27;
Anal. (C47 H 88 Cl 2 N 2 0 4 .l.2H2 0): C, H, N.
N 1 -(3,4-Bis-octadec-9-enyloxy-benzyl)-octane- l ,S-diamine, dihydrochloride salt (23):
A concentrated solution of the amine 16 (0.097 g, 0.13
mmol) in ethyl acetate was added cooled to 0° C. A total of 4
mL of a freshly prepared saturated solution of HCl in ethyl
acetate was added dropwise and the solution stirred for 1 hat
room temperature during which time a white precipitate
formed. The ethyl acetate was removed in vacuo and the
residue co-evaporated with ethyl acetate and chloroform to
give the product 23 as an off white powder (0.104 g, 9S% ); 1 H
NMR (CDC1 3 ) d 7.24 (s, lH, aryl), 7.05 (d, lH, aryl), 6.S5 (d,
lH, aryl), 5.35 (m, 4H, olefinic), 4.07 (q, 4H, OCH 2 ), 3.95 (t,
2H, benzylic), 3.07 (m, 2H, CH 2 )2.79 (m, 2H, CH 2 ), 2.05 (m,
SH, CH 2 C=C), 1.S2 (m, SH, CH 2 CH 2 0, 2xCH 2 ), 1.5S-1.21
(m, 52H, 26xCH 2 ), O.S9 (t, 6H,L:H 3 ); 13 C NMR (300 MHz,
CDC1 3 ) d 149.36, 14S.7S, 130.S5, 130.33, 129.74, 122.23,
115.56, 113.45, 69.56, 69.32, 51.56, 51.15, 45.96, 39.S6,
32.53, 30.44, 30.44, 30.23, 30.12, 30.00, 29.71, 27.61, 27.51,
27.10, 26.S3, 26.69, 24.S2, 23.77, 23.0S, 14.54; HRMS
(FAB): theory for C 51 H95 N 2 0 2 (M+l), 767.7394; found
(M+l), 767.7419;Anal. (C 51 H96 Cl 2 N 2 0 2 .0.3H 2 0): C, H, N.
2-{ 2-[2-(3,4-Bis-octadec-9-enyloxy-benzylamino )-ethoxy ]ethoxy }-ethylamine, dihydrochloride salt (24):
A concentrated solution of the amine 17 (0.14 g, O.lS
mmol) in ethyl acetate was added cooled to 0° C. A total of 4
mL of a freshly prepared saturated solution of HCl in ethyl
acetate was added dropwise and the solution stirred for 1 hat
room temperature. The ethyl acetate was removed in vacuo

and the residue co-evaporated with ethyl acetate and chloroform to give the product 24 as an off white powder (0.15 g,
9S%); 1 H NMR (CDC1 3 ) d 7.27 (s, lH, aryl), 7.00 (d, lH,
aryl), 6.S2 (d, lH, aryl), 5.33 (m, 4H, olefinic), 4.14 (m, 2H,
benzylic), 4.01 (t, 2H, OCH 2 ), 3.95 (t, 2H, OCH 2 ), 3.S7 (t,
2H, CH 2 ), 3.7S (t, 2H, CH 2 ), 3.70 (t, 4H, CH 2 ), 3.25 (t, 2H,
CH 2 ) 2.93 (m, 2H, CH 2 ), 2.02 (m, SH, CH 2 C=C), 1.S9 (m,
4H, CH 2 CH 2 0), 1.53-1.lS (m, 44H, 22xCH 2 ), O.S9 (t, 6H,
CH 3 );-1:3C NMR (300 MHz, CDC1 3 ) d 149.91, 149.62,
130.12, 130.00, 123.2S, 122.61, 115.46, 113.63, 70.22,
70.09, 69.64, 69.40, 66.50, 65.9S, 51.06, 45.0S, 40.11, 32.2S,
30.15, 29.92, 29.70, 27.60, 26.54, 26.43, 23.07, 14.54;
HRMS (FAB): theory for C49 H91 N 2 0 4 (M+l), 771.6973;
found(M+l), 771.6967;Anal. (C49 H92 Cl 2 N 2 0 4 .0.4H 2 0): C,
H,N.
N-( 4-Amino-butyl )-N'-(3 ,4-bis-octadec-9-enyloxy-benzyl )butane-1,4-diamine, tri hydrochloride salt (25):
A concentrated solution of the amine IS (0.17 g, 0.17
mmol) in ethyl acetate was added cooled to 0° C. A total of 4
mL of a freshly prepared saturated solution of HCl in ethyl
acetate was added dropwise and the solution stirred for 1 hat
room temperature during which time a white precipitate
formed. The ethyl acetate was removed in vacuo and the
residue co-evaporated with ethyl acetate and chloroform to
give the product 25 as a white powder (0.151 g, 9S%); 1 H
NMR (CDC1 3 /CH 3 0D 9:1) d 7.13 (s, lH, aryl), 7.02 (d, lH,
aryl), 6.S5 (d, lH, aryl), 5.33 (m, 4H, olefinic), 4.05 (m, 2H,
benzylic), 3.97 (t, 2H, OCH 2 ), 3.04 (m, 6H, 3xCH2 ) 2.93 (m,
2H, CH 2 ), 2.02 (m, SH, CH 2 C=C), 1.90 (m, SH, 4xCH 2 ),
1.Sl (m, 4H, CH 2 CH 2 0), 1.47 (m, 4H, 2xCH 2 ), 1.40-1.17 (m,
40H, 20xCH 2 )-;-0.S9 (t, 6H, CH 3 ); 13 C NMR (300 MHz, D 2 0)
ll 14S.94, 14S.33, 129.26, 129.19, 123.64, 122.52, 113.10,
6S.50, 6S.39, 49.96, 45.9S, 45.43, 39.S6, 31.2S, 29.lS, 29.11,
2S.93, 2S.S6, 2S.70, 2S.62, 26.64, 26.59, 25.6S, 25.62, 24.00,
22.54, 22.46, 22.11, 13.S9; HRMS (FAB): theory for
C 51 H96N 3 0 2 (M+l), 7S2.7497; found (M+l), 7S2.7495;
Anal. (C 51 H95 Cl 3 N 3 0 2 .0.6H 2 0): C, H, N.
N-[ 4-( 4-Amino-butylamino )-butyl]-N'-(3,4-bis-octadec-9enyloxy-benzyl)-butane-l,4-diamine, tetrahydrochloride salt
(26):
A concentrated solution of the amine 19 (0.253 g, 0.22
mmol) in ethyl acetate was added cooled to 0° C. A total of 5
mL of a freshly prepared saturated solution of HCl in ethyl
acetate was added dropwise and the solution stirred for 1 hat
room temperature during which time a white precipitate
formed. The ethyl acetate was removed in vacuo and the
residue co-evaporated with ethyl acetate and chloroform to
give the product 26 as a white powder (0.215 g, 9S%); 1 H
NMR (CD 3 0D) ll 7.13 (s, lH, aryl), 7.04 (d, lH, aryl), 6.9S
(d, lH, aryl), 5.33 (t, 4H, olefinic), 4.12 (m, 2H, benzylic),
4.03 (t, 2H, OCH 2 ), 3.99 (t, 2H, OCH 2 ), 3.0S (m, !OH,
5xCH 2 ), 2.9S (t, 2H, CH 2 ), 2.02 (m, SH, CH 2 C=C), 1.S9 (m,
16H, SxCH 2 ), 1.47 (m, 4H, 2xCH 2 ), 1.42-1.19 (m, 40H,
20xCH 2 ), O.S9 (t, 6H, CH 3 ); 13 C NMR (300 MHz, D 2 0) ll
149.74, 14S.90, 129.62, 129.46, 123.92, 123.71, 69.36,
6S.SS, 51.12, 46.6S, 3S.99, 32.14, 29.97, 29.Sl, 29.60, 27.36,
26.53, 24.69, 24.22, 23.14, 23.06, 22.S4, 14.05; HRMS
(FAB): theory for C 55 H 105 N4 0 2 (M+l), S53.S23S; found
(M+l), S53.S264;Anal. (C 55 H 109 Cl 4 N4 0 2 .0.6H 2 0): C, H, N.
N-[ 4-( 4-Amino-butylamino )-butyl]-3,4-bis-octadec-9-enyloxy-benzamide, dihydrochloride salt (27):
A concentrated solution the amide 20 (0.22 g, 0.22 mmol)
in ethyl acetate was added cooled to 0° C. A total of 5 mL of
a freshly prepared saturated solution ofHCl in ethyl acetate
was added dropwise and the solution stirred for 1 h at room
temperature during which time a white precipitate formed.
The ethyl acetate was removed in vacuo and the residue

5

10

15

20

25

30

35

40

45

50

55

60

65

US 7,910,363 Bl

19

20

co-evaporated with ethyl acetate and chloroform to give the
product 27 as a white powder (0.19 g, 98%); 1 H NMR
(CDC1 3 ) d 8.95 (br s, 2H, R 2 WH 2 ), 8.20 (br s, 3H, RWH 3 ),
7.45 (m, 2H, aryl), 6.78 (m, lH, aryl), 5.33 (m, 4H, olefinic),
3.95 (m, 4H, OCH 2 ), 3.38 (m, 2H, CH 2 ), 3.11 (m, 2H, CH 2 ),
3.01 (m, 4H, 2xCH 2 ), 2.08-1.89 (m, 14H, 7xCH 2 ), 1.71 (m,
6H, 3xCH2 ), 1.47-1.18 (m, 44H, 20xCH 2 ), 0.89 (t, 6H, CH 3 );
HRMS (FAB): theory for C 51 H 94N 3 0 3 (M+l), 796.7290;
found (M+ 1), 796.7249; Anal. (C 51 H 95 Cl 2 N 3 0 3 . l .6H 2 0): C,
H,N.
N-{ 4-[ 4-( 4-Amino-butylamino )-butylamino ]-butyl }-3,4bis-octadec-9-enyloxy-benzamide, trihydrochloride salt
(28):
A concentrated solution of the amide 21 (0.22 g, 0.19
mmol) in ethyl acetate was added cooled to 0° C. A total of 5
mL of a freshly prepared saturated solution of HCl in ethyl
acetate was added dropwise and the solution stirred for 1 hat
room temperature during which time a white precipitate
formed. The ethyl acetate was removed in vacuo and the
residue co-evaporated with ethyl acetate and chloroform to
give the product 28 as a white powder (0.18 g, 98% ); 1 H NMR
(CDC1 3 /CH 3 0D 9:1) d 7.42 (m, 2H, aryl), 6.78 (m, lH, aryl),
5.33 (m, 4H, olefinic), 4.03 (m, 4H, OCH 2 ), 3.41 (m, 2H,
CH 2 ), 3.01 (m, !OH, 5xCH 2 ), 2.08-1.66 (m, 24H, 12xCH2 ),
1.71 (m, 6H, 3xCH2 ), 1.56-1.13 (m, 44H, 20xCH 2 ), 0.89 (t,
6H, CH 3 ); HRMS (FAB): theory for C 55 H 105 N 4 0 3 (M+l),
867.8025; found (M+l), 867.8022; Anal. Calcd for
(C 55 H 105 Cl 3 N 4 0 3 .l.5H2 0): C, H, N.
Advantages of the present invention include the surprising
discovery that compound (#26) is much more efficient in
delivering DNA into a target cell than the commercial Lipofectamine™ transfection agent. 39 This efficiency, coupled
with the straightforward synthesis we developed for this
material makes this product commercially viable to pursue.
Uses of compound #26 and other compounds herein disclosed include use as smart anticancer agents which recognize and selectively deliver "cargoes" to specific cell types.
The cargoes could be either 'corrective' DNA which repairs
or replaces the cancerous genetic lesion and allows forthe cell
to heal itself. Alternatively, one could deliver toxic compounds such as the plant toxin saporin, which targets cell
protein synthesis ability. Blocking protein synthesis is a toxic
event for the cell. Therefore, one could envision delivering
toxic compounds selectively to cancer cells to kill them, even
in the presence of normal healthy cells. Coadministration of
the agent saporin with a lipopolyamine was shown to promote
entry of the agent into cells by the cell's own polyamine
transporter system. These results were published in FEBS J.,
274 (2007) 4825-4836, a paper which is noted above and
which has been incorporated herein by reference in its
entirety.
A deficiency in previously known compounds is their
lower efficiency of transfection and their inability to target
specific cell types via the polyamine transport system.

R 1 and R 2 may be the same or may be different and comprise a long hydrocarbon chain which is between six and
eighteen carbons long and either contains or does not contain
units of unsaturation. For example, the chain could be derived
from the C 18 oleic acid and attached via an ester linkage or via
an ether linkage and an oleyl group. The chains can range
from lauryl, stearic, myristic and oleic acids.
R 3 is a polycation comprising a polyamine side chain.
These aliphatic polyamine side chains can range from mono
amines to octaamines with carbon spacer groups ranging
from two to six in between the nitrogen centers. These can
also be branched systems as well. For example:
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where a-g range from two to six
Note: other polycationic moieties may be used in place of the
polyamine. More biofriendly cations like polyhistine, polyarginine, polylysine or polyornithine peptides could be
used. These could be in the all L, all D or mixed L,D forms. In
addition, the hydrochloride salts as well as other pharmaceutically acceptable salt forms of compound 1 could be used.
II.
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-NH-(CH2)aNH(CH2)bNH(CH2)cNH(CH2)dNH
(CH2)eNH(CH2)_,NH2
-NH-(CH2)aNH(CH2)bNH(CH2)cNH(CH2)dNH
(CH2)eNH(CH2)_,NH(CH2),,NH2
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-NH-(CH2laNH(CH2)bNH(CH2)cNH(CH2)dNH2
-NH-(CH2laNH(CH2)bNH(CH2)cNH(CH2)dNH
(CH2)eNH2
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R3

R 1 and R 2 are the same or different and are comprised of a
long hydrocarbon chain which is between six and eighteen
carbons long and either contains or does not contain units of
unsaturation. For example, the chain could be derived from
the C 18 oleic acid and attached via an ester linkage or via an
ether linkage and an oleyl group. The chains can range from
lauryl, stearic, myristic and oleic acids.
R 3 is a polycations comprised of a polyamine side chain.
These aliphatic polyamine side chains can range from mono
amines to octaamines with carbon spacer groups ranging
from two to six in between the nitrogen centers. These can
also be branched systems as well.
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-NH-(CH2)aNH(CH2)bNH2
-NH-(CH2laNH(CH2)bNH(CH2)cNH2

10
-NH-(CH2)aNH(CH2)bNH(CH2)cNH(CH2)dNH
(CH2)eNH2
-NH-(CH2)aNH(CH2)bNH(CH2)cNH(CH2)dNH
(CH2)eNH(CH2)_iNH2

15

-NH-(CH2)aNH(CH2)bNH(CH2)cNH(CH2)dNH
(CH2)eNH(CH2)_iNH(CH2),,NH2

where a-g range from two to six
Note: other polycationic moieties may be used in place of the
polyamine. More biofriendly cations like poly-histine, polyarginine, polylysine or polyomithine peptides could be
used. These could be in the all L, all D or mixed L,D forms. In
addition, the hydrochloride salts as well as other pharmaceutically acceptable salt forms of 2 could be used as well.
III. Pharmaceutical compositions of either 1 and/or 2 along
with a neutral lipid (e.g., DOPE) and a therapeutic agent such
as a DNA plasmid, siRNA (gene silencing agent), or toxic
compound. The DNA plasmid could be a corrective gene to
repair or replace a damaged gene within the cell. The siRNA
could be a RNA molecule designed to silence a bad gene to
provide a positive therapeutic outcome. The toxic compound
could be a toxic drug that kills the cell like methotrexate,
doxorubicin, cis platin, taxol, or other toxins like saporin or
ricin which target specific critical cell functions.
Summary. The invention will allow forthe selective delivery of therapeutic agents to cancer cells via the polyamine
transport system. The technology is predicated upon the fact
that certain cancer cells readily import polyamines from their
environment. This property provides an opportunity to target
these cells via their selective uptake of these cationic materials. The patented materials can also delivery other therapeutic
agents to cells such as DNA plasmids, RNA for gene silencing therapies, and proteins which repair or destroy cells. The
technology also allows for enhanced transfection of cells by
utilizing this special uptake pathway to deliver new genes,
nucleic acids and proteins into cells.
Accordingly, in the drawings and specification there have
been disclosed typical preferred embodiments of the invention and although specific terms may have been employed, the
terms are used in a descriptive sense only and not for purposes
of limitation. The invention has been described in considerable detail with specific reference to these illustrated embodiments. It will be apparent, however, that various modifications and changes can be made within the spirit and scope of
the invention as described in the foregoing specification and
as defined in the appended claims.
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That which is claimed:
1. A vector effective in delivering an agent into a cell, said
vector comprising a cationic lipid selected from compounds
(25), (26), (27), (28), their pharmaceutically acceptable salts
and combinations thereof.
2. The vector of claim 1, wherein said agent comprises a
polynucleotide.
3. The vector of claim 1, wherein said agent comprises
DNA.
4. The vector of claim 1, wherein Said agent comprises a
trans gene.
5. The vector of claim 1, wherein said agent is toxic forthe
cell.
6. A polyamine cationic lipid selected from compounds
25), (26), (27), (28), their pharmaceutically acceptable salts
and combinations thereof.
7. The lipid of claim 6, wherein the selected compound is
compound (26) or a pharmaceutically acceptable salt thereof.
8. A polyamine cationic lipid vector effective in delivering
an agent into a cell in enhanced levels by being recognized by
the cell's polyamine transport system, said vector comprising
compound (26) or a pharmaceutically acceptable salt thereof.
9. The vector of claim 8, wherein said agent comprises a
polynucleotide.
10. The vector of claim 8, wherein said agent comprises
DNA.
11. The vector of claim 8, wherein said agent comprises a
trans gene.
12. Thevectorof claim 8, wherein said agent is toxic forthe
cell.
13. A method of delivering an agent into a cell, the method
comprising associating the agent with a polyamine cationic
lipid selected from compounds (25), (26), (27), (28), their
pharmaceutically acceptable salts and combinations thereof
and contacting the cell therewith.
14. The method of claim 13, wherein said agent comprises
a polynucleotide.
15. The method of claim 13, wherein said agent comprises
DNA.
16. The method of claim 13, wherein said agent comprises
a transgene.

US 7,910,363 Bl

25

26

17. The method of claim 16, wherein said agent is toxic for
the cell.
18. A method of delivering enhanced levels of an agent into
a cell, the method comprising associating the agent with a
polyamine cationic lipid according to compound (26) or a
pharmaceutically acceptable salt thereof and effective in
being recognized by a polyamine transport system in the cell.
19. The method of claim 18, wherein said agent comprises
a polynucleotide.
20. The method of claim 18, wherein said agent comprises

24. The method of claim 23, wherein said agent comprises
a polynucleotide.
25. The method of claim 23, wherein said agent comprises

DNA.
21. The method of claim 18, wherein said agent comprises
a transgene.
22. The method of claim 18, wherein said agent is toxic for
the cell.
23. A method of delivering enhanced levels of an agent into
target cells having an upregulated polyamine transporter, the
target cells being among a population of normal cells, the
method comprising associating the agent with a polyamine
cationic lipid according to compound (26) or a pharmaceutically acceptable salt thereof and contacting the cell population therewith so as to preferentially deliver the polynucleotide into the target cells via the upregulated polyamine
transporter system.

DNA.
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26. The method of claim 23, wherein said agent comprises
a transgene.
27. The method of claim 23, wherein said agent is toxic for
the cell.
28. A method of treating a target cell having an upregulated
polyamine transporter, the method comprising associating an
agent with a polyamine cationic lipid according to compound
(26) or a pharmaceutically acceptable salt thereof and contacting the cell therewith.
29. The method of claim 28, wherein said agent comprises
a polynucleotide.
30. The method of claim 28, wherein said agent comprises

DNA.
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31. The method of claim 28, wherein said agent comprises
a transgene.
32. The method of claim 28, wherein said agent is toxic for
the cell.
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